Open menu
 

Nanobiotechnology and Nanomedicine Companies

 

(Links listed alphabetically)

 
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | All
 

Showing results 51 - 75 of 252

 
The company develops its proprietary E-SPR (Enhanced Surface Plasmon Resonance) technology platform for the detection of molecular interactions.
The company has a polymer micro-system technology platform comprising core intellectual property in the areas of polymer multilevel micro- and nano-replication, plastic micro-fluidic chip fabrication and photonics integration, to provide unique products for point-of-use analytical applications.
A life sciences R&D company with a special focus on skin cell biology. The company has established proprietary technologies for nano-liposomal formulation techniques.
The company develops revolutionary microliter and nanoliter scale technology platforms for life sciences and drug discovery research.
Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases. The company is pioneering an integrative way to discover molecular entities with new mechanisms of action purposely designed for our proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together they can make medicines more targeted, more effective and more tolerable.
Calevia aims to harness the power of molecular targeting technologies and the heat-generation capacity of MesoGraf Xide, a photo-responsive graphene material, to create bio-conjugates designed to home-in on - and destroy - cancer cells in a non-invasive, non-pharmacological and efficient manner.
A leading provider of cutting-edge technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper has compiled numerous best-in-class solutions and is aggressively innovating new technologies to bridge the gaps that exist in bringing in vitro assays to in vivo results and ultimately into cures for human disease.
Camurus specializes in the development of pharmaceuticals based on advanced and effective innovative nanoscale drug delivery systems that optimize the bioavailability and therapeutic performance of a wide range of difficult substances, including: peptides, proteins, and insoluble small molecules.
Carestream Molecular Imaging is a leading provider of Kodak branded in vivo and in vitro optical molecular imaging solutions for life science and molecular biology research.
The company develops new treatments for cancer based on a portfolio of delivery technologies including liposomes, polymers and nanotechnologies.
Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.
An instrumentation and cell-based assay company developing technologies that accurately mimic cellular behavior in vivo for cell-based screening in drug discovery.
Celsense is a biotechnology company offering novel MRI contrast agents (fluorochemical nanoparticles) that allow scientists and clinicians to monitor the position and quantity of transplanted cells non-invasively in vivo.
Commercializes a nano and micron sized ceramic spheres technology that provides encapsulation and controlled release of active molecules for a variety of applications including drug delivery, cosmeceuticals and speciality chemicals.
The company develops nanoparticle-based gene therapies for eye disease.
The company focuses on the production of novel active pharmaceutical ingredients and nanomedicines.
Chemicell develops and produces innovative bioseparation- gene transfection and detection systems based on magnetic nano- and microparticles.
Chemicon offers molecular biology research tools. Included are mRNA expression analysis assays via RT-PCR and PCR amplication methods for apoptosis, cancer, cytokines, signal transduction, MMPs and ECM using colorimetric or bioluminescent formats
The company develops and sells tools for biomedical research based on nanotechnologies. Our products range from nanoparticles in suspensions to engineered surfaces for applications within stem cell research.
The group is involved in the rapidly developing field of nanobiopharmacy. It focuses on tissue engineering (e.g. scaffolds for cartilage and skin replacement, differentiation of stem cells into chondrocytes), wound healing, gene therapy and targeted drug delivery (using above mentioned polysaccharides and their conjugates). The research and innovation is an integral part of the company activities. Due to recent investments in the state-of-the art laboratory equipment and experienced and motivated scientists the company creates a unique center for regenerative medicine research, including various in-vitro and in-vivo tests.
Developed a technology to compact DNA into complexes containing only a single molecule of DNA, resulting in a volume 30-1000 times smaller than other complexes. This simple difference makes Copernicus' "DNA nanoparticles" highly stable and uniquely able to deliver DNA to the nuclei of non-dividing human cells - which includes most cells in the body.
Develops the Emulsiphan™ nanoparticle tumor targeting technology.
Covaris, Inc. is a life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise and accurate energy to biological and chemical samples.
Curiox is a bioinstrumentation company enabling the miniaturization of heterogeneous bioassay for researchers working in life sciences, drug discovery, and diagnostics. Curiox's patented miniaturization platform, DropArray, provides up to 1,000 times savings in sample and reagent consumption, and up to 10 times reduction in assay time.
The Company is developing a pipeline of multifunctional, next-generation therapeutics, binding known anti-cancer agents to its patented colloidal gold tumor-targeting nanotechnology.